Compare Merck & Co., Inc. (MRK) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SanDisk — how do they compare? Merck & Co., Inc. trades at $148.25 (market cap $366.28B), while SanDisk trades at $1,744.86 (market cap $254.47B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.29% dividend while SanDisk pays none. Which is the better fit depends on your goals.
| MRK | SNDK | |
|---|---|---|
Market Cap | $366.28B | $254.47B |
Sector | Health | Technology |
52-Week High | $156.43 | $2.34K |
52-Week Low | $77.60 | $73.92 |
Enterprise Value | $413.04B | $249.89B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SNDK trades at $1,737.99, down 0.12% on the day, with a neutral technical signal. The stock has surged over 500% in 2026, driven by AI-driven memory demand, and is set to join the S&P 500. Recent quarters show strong EPS beats, with Q2 2026 actual EPS of $39.25 surpassing the $34.96 estimate. Fundamentals are mixed, with a net loss in 2025 but a projected profit margin of 56.46% for 2026, supported by high gross margins and robust ROE of 91.64%.
Outlook is bullish due to AI memory supercycle tailwinds and contracted revenue floors, but risks include volatility from insider selling and valuation concerns. Analysts are overwhelmingly positive, with 87.5% buy ratings and a consensus price target of $2,330, implying 34% upside. Investors should weigh high growth potential against execution risks in a cyclical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
